[HTML][HTML] The Chagas disease study landscape: A systematic review of clinical and observational antiparasitic treatment studies to assess the potential for establishing …

BJ Maguire, P Dahal, S Rashan, R Ngu… - PLoS neglected …, 2021 - journals.plos.org
Background Chagas disease (CD), caused by the parasite Trypanosoma cruzi, affects ~6–7
million people worldwide. Significant limitations still exist in our understanding of CD. …

[HTML][HTML] A scoping review of registry captured indicators for evaluating quality of critical care in ICU

I Jawad, S Rashan, C Sigera, J Salluh… - Journal of intensive …, 2021 - Springer
Background Excess morbidity and mortality following critical illness is increasingly attributed
to potentially avoidable complications occurring as a result of complex ICU management (…

[HTML][HTML] Baseline results of a living systematic review for COVID-19 clinical trial registrations

BJ Maguire, ARD McLean, S Rashan… - Wellcome Open …, 2020 - ncbi.nlm.nih.gov
Background: Since the coronavirus disease 2019 (COVID-19) outbreak was first reported in
December 2019, many independent trials have been planned that aim to answer similar …

[HTML][HTML] Definitions matter: heterogeneity of COVID-19 disease severity criteria and incomplete reporting compromise meta-analysis

PJ Guérin, ARD McLean, S Rashan… - PLOS global public …, 2022 - journals.plos.org
Therapeutic efficacy in COVID-19 is dependent upon disease severity (treatment effect
heterogeneity). Unfortunately, definitions of severity vary widely. This compromises the meta-…

[HTML][HTML] Serious adverse events following treatment of visceral leishmaniasis: A systematic review and meta-analysis

…, A Hawryszkiewycz, S Rashan… - PLoS Neglected …, 2021 - journals.plos.org
Background Despite a historical association with poor tolerability, a comprehensive review
on safety of antileishmanial chemotherapies is lacking. We carried out an update of a …

[HTML][HTML] Protocol and statistical analysis plan for the mega randomised registry trial comparing conservative vs. liberal oxygenation targets in adults with nonhypoxic …

…, AD Nichol, S Olatunji, A Rashan, S Rashan… - Critical Care and …, 2023 - Elsevier
Background The effect of conservative vs. liberal oxygen therapy on 90-day in-hospital
mortality in adults who have nonhypoxic ischaemic encephalopathy acute brain injuries and …

[HTML][HTML] Post-kala-azar dermal leishmaniasis (PKDL) drug efficacy study landscape: A systematic scoping review of clinical trials and observational studies to assess …

…, R Kumar, P Dahal, A Munir, S Rashan… - PLOS Neglected …, 2024 - journals.plos.org
Background Post-kala-azar dermal leishmaniasis (PKDL) is a dermatosis which can occur
after successful treatment of visceral leishmaniasis (VL) and is a public health problem in VL …

[HTML][HTML] Infectious diseases data Observatory (IDDO) visceral Leishmaniasis library of clinical therapeutic studies: A protocol for a living systematic review of clinical …

S Singh-Phulgenda, S Rashan… - Wellcome Open …, 2022 - wellcomeopenresearch.org
Introduction: Visceral leishmaniasis (VL) is a vector-borne disease caused by protozoan
parasites of the genus Leishmania. The disease is endemic in parts of South Asia, East Africa, …

[HTML][HTML] Protocol for a systematic review of the evidence-based knowledge on the distribution, associated risk factors, the prevention and treatment modalities for …

BJ Maguire, P Shrestha, S Rashan… - Wellcome Open …, 2023 - wellcomeopenresearch.org
Introduction: Noma (cancrum oris) is a devastating opportunistic infection resulting in severe
tissue destruction that affects mouth and oro-facial structures. There are substantial gaps in …

[HTML][HTML] The fragmented COVID-19 therapeutics research landscape: a living systematic review of clinical trial registrations evaluating priority pharmacological …

ARD McLean, S Rashan, L Tran… - Wellcome Open …, 2022 - wellcomeopenresearch.org
Background: Many available medicines have been evaluated as potential repurposed
treatments for coronavirus disease 2019 (COVID-19). We summarise the registered study …